Edwin M Horwitz
Overview
Explore the profile of Edwin M Horwitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
2878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Blanc K, Dazzi F, English K, Farge D, Galipeau J, Horwitz E, et al.
Cytotherapy
. 2025 Jan;
PMID: 39864015
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought...
2.
Goss K, Horwitz E
Cytotherapy
. 2024 Nov;
27(2):137-145.
PMID: 39530970
Single-cell RNA-sequencing (scRNAseq) was first introduced in 2009 and has evolved with many technological advancements over the last decade. Not only are there several scRNAseq platforms differing in many aspects,...
3.
Parwani K, Branella G, Burnham R, Burnham A, Schiaffino Bustamante A, Foppiani E, et al.
Front Immunol
. 2024 Mar;
15:1331322.
PMID: 38487542
Vγ9Vδ2 T cells represent a promising cancer therapy platform because the implementation of allogenic, off-the-shelf product candidates is possible. However, intravenous administration of human Vγ9Vδ2 T cells manufactured under good...
4.
Levine B, Pasquini M, Connolly J, Porter D, Gustafson M, Boelens J, et al.
Nat Med
. 2024 Jan;
30(2):338-341.
PMID: 38195751
No abstract available.
5.
Chen C, Zheng H, Horwitz E, Ando S, Araki K, Zhao P, et al.
Sci Adv
. 2023 Dec;
9(49):eadf9522.
PMID: 38055827
Mitochondria use different substrates for energy production and intermediatory metabolism according to the availability of nutrients and oxygen levels. The role of mitochondrial metabolic flexibility for CD8 T cell immune...
6.
Burnham A, Foppiani E, Goss K, Jang-Milligan F, Kamalakar A, Bradley H, et al.
Cytotherapy
. 2023 Oct;
25(12):1277-1284.
PMID: 37815775
Background Aims: Mesenchymal stromal cells (MSCs) are polymorphic, adherent cells with the capability to stimulate tissue regeneration and modulate immunity. MSCs have been broadly investigated for potential therapeutic applications, particularly...
7.
Sivasami P, Elkins C, Diaz-Saldana P, Goss K, Peng A, Hamersky 4th M, et al.
Immunity
. 2023 Jul;
56(8):1844-1861.e6.
PMID: 37478855
Obesity is a major risk factor for psoriasis, but how obesity disrupts the regulatory mechanisms that keep skin inflammation in check is unclear. Here, we found that skin was enriched...
8.
Scheiber A, Clark C, Kaito T, Iwamoto M, Horwitz E, Kawasawa Y, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35162938
Extracellular vesicles (EVs) released by bone marrow stromal cells (BMSCs) have been shown to act as a transporter of bioactive molecules such as RNAs and proteins in the therapeutic actions...
9.
Burnham A, Burnham P, Horwitz E
J Clin Med
. 2021 Jul;
10(12).
PMID: 34207118
Olfactory neuroblastoma (ONB) is a rare neuroepithelial-derived malignancy that usually presents in the nasal cavity. The rarity of ONB has led to conflicting reports regarding associations of patient age and...
10.
Hasgur S, Desbourdes L, Relation T, Overholt K, Stanek J, Guess A, et al.
Cytotherapy
. 2021 Mar;
23(5):411-422.
PMID: 33781710
Mesenchymal stromal cells (MSCs) possess remarkable tumor tropism, making them ideal vehicles to deliver tumor-targeted therapeutic agents; however, their value in clinical medicine has yet to be realized. A barrier...